Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1Dermatologic 1Breast 1

Conditions

Triple Negative Breast Neoplasms 1Pancreatic Neoplasms 1Neoplasm Metastasis 1Melanoma 1Esophageal Squamous Cell Carcinoma 1Colorectal Neoplasms 1

Interventions

Paclitaxel 18pembrolizumab 16Cisplatin 16Fluorouracil 15Irinotecan 13tislelizumab 9Oxaliplatin 8Nivolumab 8Docetaxel 8Leucovorin 6Capecitabine 5spartalizumab 4Levoleucovorin 4Carboplatin 4lenvatinib 3durvalumab 3Radiotherapy 3Drug Therapy 3toripalimab 2sintilimab 2regorafenib 2elgemtumab 2atezolizumab 2Itraconazole 2Injections 2Gemcitabine 2Bevacizumab 2130-nm albumin-bound paclitaxel 2tremelimumab 1sitravatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Esophageal Squamous Cell Carcinoma × LGK974 × Clear all
NCT01351103 2025-06-13

A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands

Novartis

Phase 1 Completed
185 enrolled
BreastDermatologicGastrointestinal

Esophageal Squamous Cell Carcinoma, Melanoma, Pancreatic Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡